This metadata record and it's attached files make statements about the kinds of data collected as part of this research, and set out policies for governance of that data, now and in the future.
Description: Project running a clinical trial aimed at identifying and validating the health benefits of Greenshell mussels, specifically looking at their potential anti-inflammatory qualities for improved joint and bone health and increased mobility.
This clinical trial was conducted to determine bioavailability of fatty acid between different Greenshell™ mussel formats (oil, powder, food ingredient and half-shell unprocessed whole mussel). The wider project also included:
- measurement of the biochemical changes in composition of GSM over an annual cycle,
- development of rapid analytical methods for measuring GSM composition by near-infrared technologies (NIR),
- development of an in-vivo model in rats to assess GSM effects on metabolic syndrome (obesity), inflammation, osteoarthrosis and osteoporosis,
- development of new food formats that contain GSM
Publisher
University of AucklandTemporal coverage: start
2016-01-01Temporal coverage: end
2019-01-01HVN Project / Programme Name
Musseling Up 1.0Data access requirements
Due to the nature of the research, due to commercial outcomes of the research, supporting data is not available.Principal investigator organisation
Cawthron InstituteCollaborating researchers and affiliations
Principal Investigators:
Dr Matt Miller, Cawthron Institute
Investigators:
- Donato Romanazzi (Cawthron Institute),
- Professor Charles Eason (Cawthron Institute)Data description
Outcomes of the Study and associated data
Primary Outcome
- Biolavailability of n-3 LC PUFA in different formats of GSM (frozen half-shell GSM, GSM food ingredient, GSM powder and GSM oil extract) at 12 and 48 hours following single dose intakes.
Available data: plasma concentration of n-3 LC PUFA, maximum measured plasma concentration of n-3 LC PUFA (Cmax), Time of the maximum measured plasma concentration of n-3 LC PUFA (Tmax), incremental area under the plasma concentration-time curve of n-3 LC PUFA (AUC)
Secondary Outcomes
- Bioavailability of eicosapentaenoic acid (EPA) in different formats of GSM following single dose intakes
- Bioavailability of docosahexaenoic acid (DHA) in different formats of GSM following single dose intakes
Available data: plasma concentration of EPA, maximum measured plasma concentration of EPA (Cmax), Time of the maximum measured plasma concentration of EPA (Tmax), incremental area under the plasma concentration-time curve of EPA (AUC), plasma concentration of DHA, maximum measured plasma concentration of DHA (Cmax), Time of the maximum measured plasma concentration of DHA (Tmax), incremental area under the plasma concentration-time curve of DHA (AUC)
Other outcomes:
- Demographics
- Adverse events
- Clinical screening and medical historyPrincipal investigator contact email
matt.miller@cawthron.org.nz
